Xanthelasma palpebrarum: a new side effect of nilotinib

Chronic myeloid leucaemia (CML) is a chronic myeloproliferative disorder characterised by a reciprocal translocation between the chromosomes 9 and 22 resulting in constitutionally active tyrosine kinase signalling. BCR-ABL tyrosine kinase inhibitors (TKIs) are highly effective molecules in the treat...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2016-01, Vol.2016, p.bcr2015213511
Main Authors: Sayin, Irmak, Ayli, Meltem, Oğuz, Ali Kemal, Cengiz Seval, Güldane
Format: Article
Language:English
Subjects:
Adult
Alcohol
Asia
Cholesterol
Drug dosages
Eyelid Diseases - chemically induced
Female
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Hematology
Humans
Laboratories
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Lipids
Lipoproteins
Neutrophils
Patients
Plasma
Protein Kinase Inhibitors - adverse effects
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyrimidines - adverse effects
Triglycerides
White
Xanthomatosis - chemically induced
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myeloid leucaemia (CML) is a chronic myeloproliferative disorder characterised by a reciprocal translocation between the chromosomes 9 and 22 resulting in constitutionally active tyrosine kinase signalling. BCR-ABL tyrosine kinase inhibitors (TKIs) are highly effective molecules in the treatment of CML. Unfortunately, these novel therapeutic agents are accompanied by various side effects, and haematological, cutaneous and metabolic abnormalities are among the most prevalent. Nilotinib, a second-generation TKI, has been shown to cause both—cutaneous lesions and lipid profile abnormalities. We present two CML cases developing xanthelasma palpebrarum while receiving nilotinib. Case 1 also acquired a lipid abnormality following the start of nilotinib therapy, while case 2 meanwhile stayed normolipidemic. In addition to a low cholesterol diet, atorvastatin was prescribed to case 1. Currently, both cases are normolipidemic and continuing their nilotinib therapy. Xanthelasma palpebrarum secondary to nilotinib therapy is new to the literature.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2015-213511